South Korean biopharmaceutical company Celltrion (KRX: 068270) has presented positive long-term efficacy and safety data for its infliximab biosimilar in the treatment of Crohn’s disease (CD) and ulcerative colitis (UC). The biosimilar offers the advantage of subcutaneous administration, providing a more convenient alternative to Johnson & Johnson’s (J&J; NYSE: JNJ) originator Remicade for patients with moderately to severely active CD and UC.
The data, which spans up to 102 weeks of treatment, shows that Celltrion’s biosimilar maintains sustained efficacy in both CD and UC, with no new safety concerns reported. Furthermore, the drug achieved mucosal healing in patients with CD by the 22nd week of treatment.- Flcube.com
